mRNA and gene editing: Late breaking therapies in liver diseases.

Authors:
Zabaleta N; Torella L; Weber ND; Gonzalez-Aseguinolaza G.

Journal:
Hepatology

Publication Year: 2022

DOI:
10.1002/hep.32441

PMCID:
PMC9546265

PMID:
35243655

View on PubMed View on PMC View Publisher

Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal

View All Papers from This Journal

Transparency Score

2/6

33.3% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"CONFLICT OF INTEREST Dr. Gonzalez‐Aseguinolaza owns stock in and is the chief scientific officer and cofounder of Vivet Therapeutics. Dr. Weber owns stock in and is employed by Vivet Therapeutics."

Funding Disclosure

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025

mRNA and gene editing: Late breaking therapies in liver diseases.

Journal Information

Publication Details

Related Papers from Same Journal

A global action agenda for turning the tide on fatty liver disease.

c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.

Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex wi…

Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hep…

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.

Transparency Score

Transparency Indicators

Core Indicators

Additional Indicators

Assessment Info